The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Blood Biomarkers for Monitoring Response to anti-EGFR Therapy


Stanford Reference:

13-017


Abstract


This invention enables the response of a cancer patient to an anti-EGFR targeted therapeutic to be monitored through the measurement of a single protein (PRDX6) within a blood sample. Changes in PRDX6 levels during the course of therapy can be used to determine if the patient is responding to the anti-EGFR drug or has acquired resistance to it. Patient response can be monitored frequently and over the long term in a safe, simple and cost-effective manner, such that the development of treatment resistance can be detected as soon as possible. Advantages over traditional imaging approaches include ease of blood sample collection, absence of ionizing radiation, and low cost of sample analysis. The research team has developed a PRDX6 temporal signature of response to anti-EGFR therapies and validated in mouse models.


Fig. description- Monitoring response to anti-EGFR therapy using blood biomarkers. Blood samples are collected prior to the start of therapy and then at regular intervals during the course of therapy. Changes in the concentration of one or more predictive biomarkers can be used to determine at an early stage if the patient is responding to treatment, and subsequently to monitor long-term response in order to detect the onset of resistance as soon as possible.

Stage of Research:
Continued research with focus on validating PRDX6 levels in human patients.



Applications


  • Cancer therapy monitoring, specifically to anti-EGFR therapeutics, primarily in non small cell lung cancer (NSCLC), also potentially colorectal cancer and other cancer types for which anti-EGFR agents are used

Advantages


  • Advantages vs. current imaging methods:
    • Ease of blood sample collection
    • Samples can be analyzed quickly and inexpensively for multiple biomarkers using standard proteomic assays
    • Reduces exposure to ionizing radiation
    • Better tracking of therapeutic response - changes in the levels of biomarkers associated with key oncogenic processes may occur several weeks or months before a corresponding change in tumor size is detected on imaging
    • Can be used for both short term and long term therapy monitoring

Publications



Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 5/26/2016
 

Licensing Contact


Irit Gal, Senior Licensing Associate
650-723-1586 (Business)

Online Non-Disclosure Agreement (NDA)





[-] Map/Timeline

92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)
96-113 Semiconductor Light Emitting Devices for Phototherapy of Jaundiced Newborns or Circadian Rhythm Disorders

more technologies

Related Keywords


diagnostic: elisa   diagnostic: marker   therapeutic: anticancer   therapeutic: proteins   healthcare: diagnostic tool   healthcare: non-invasive device   healthcare: therapeutic   medical devices: diagnostics and measurement   therapy monitoring   EGFR   biomarkers   biomarker: cancer   biomarkers & disease models for oncology   biomarkers for diagnostics   lung cancer   lung cancer diagnostic   lung cancer markers   molecular biomarkers   molecular biomarkers cancer   non-small cell lung cancer   protein biomarker   drug monitoring   patient monitoring   13-017   
 

   

  

Also of Interest...
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)
96-113 Semiconductor Light Emitting Devices for Phototherapy of Jaundiced Newborns or Circadian Rhythm Disorders

Recently Viewed...
S13-017 Blood Biomarkers for Monitoring Response to anti-EGFR Therapy